Designing clinical trials for the treatment of delirium

Journal of Psychosomatic Research
P T TrzepaczShuyu Zhang

Abstract

There is a large body of empirical evidence for the usefulness of pharmacological treatment of delirium though there is a relative dearth of double-blind randomized clinical trials and few that are placebo controlled. There are no registration quality double-blind, randomized, placebo-controlled trials that evaluate efficacy and safety, nor is there a regulatory body in any country that has approved a drug with an indication to treat delirium. Reasons include inadequate training for design and implementation of clinical trials, too few patients at a given research site to adequately power a study, confounding variables such as dementia, multifactorial underlying etiologies that are difficult to control, inadequate understanding of the neuropathophysiology of delirium that could theoretically guide a choice of drugs, referral populations where the primary physician may not be the one interested in pursuing the research, confounding factors for attribution of safety signals, and lack of funding for an adequately powered trial outside of the pharmaceutical industry. This article provides basic information aimed at educating physicians and other clinicians about design and implementation considerations to conduct an adequately powe...Continue Reading

References

Dec 15, 1990·Annals of Internal Medicine·S K InouyeR I Horwitz
Jan 1, 1988·Psychiatry Research·P T TrzepaczJ Greenhouse
Jan 1, 1994·The Journal of Neuropsychiatry and Clinical Neurosciences·M M PlattP B Jacobsen
Nov 1, 1996·Psychosomatics·R P HartL E Rutherford
Mar 1, 1997·Journal of Pain and Symptom Management·W BreitbartS Passik
Apr 17, 2001·Annals of Internal Medicine·D G AltmanUNKNOWN CONSORT GROUP (Consolidated Standards of Reporting Trials)
Jun 30, 2001·Intensive Care Medicine·N BergeronY Skrobik
Jul 13, 2001·The Journal of Neuropsychiatry and Clinical Neurosciences·P T TrzepaczN Jimerson
Jun 1, 2004·The American Journal of Psychiatry·Nathan HerrmannKrista L Lanctôt
Jan 7, 2005·American Journal of Alzheimer's Disease and Other Dementias·Rita MorettiGiuseppe Cazzato
Mar 2, 2005·Journal of Medical Ethics·D AdamisA J D Macdonald
Sep 27, 2005·Journal of the American Geriatrics Society·Kees J KalisvaartWillem A van Gool
Aug 19, 2008·Journal of Psychosomatic Research·Rachel HoltJohn Young

❮ Previous
Next ❯

Citations

Mar 1, 2012·Journal of Child and Adolescent Psychopharmacology·Susan Beckwitt TurkelC Jane Tavaré
Jul 28, 2012·Psychiatry and Clinical Neurosciences·Yasuhiro KishiSteven Thurber
Aug 9, 2013·Drug Design, Development and Therapy·Benchalak ManeetonKaweesak Chittawatanarat
Mar 24, 2011·Harvard Review of Psychiatry·John W Devlin, Yoanna Skrobik
Mar 12, 2013·Revista española de geriatría y gerontología·Nicolas Martinez Velilla, José G Franco
Aug 21, 2013·Psychosomatics·Andreas Baranyi, Hans-Bernd Rothenhäusler
Oct 20, 2010·Journal of Psychosomatic Research·Tayyeb A TahirJonathan I Bisson
May 6, 2011·Journal of Gerontological Nursing·Sean P ClarkeRima Styra
Apr 20, 2012·International Journal of Older People Nursing·Andrea YevchakDonna Fick
Oct 19, 2012·Acta Anaesthesiologica Scandinavica·H WøienA Stubhaug
Mar 24, 2016·Journal of the American Geriatrics Society·Xin DuanGuang-Yu Ma
Dec 28, 2011·Journal of Psychosomatic Research·Tayyeb A TahirJonathan Bisson
Aug 2, 2012·Journal of Psychosomatic Research·Daniel FarewellJonathan Bisson
Dec 6, 2014·Age and Ageing·Dimitrios AdamisDavid Meagher
Nov 22, 2013·The Annals of Pharmacotherapy·Christopher J MichaudKaren J McAllen
Jan 22, 2019·Journal of the American Geriatrics Society·Noll L CampbellMalaz A Boustani
Apr 4, 2017·Nursing in Critical Care·Tanya MailhotAndré Denault
Jan 27, 2019·Journal of the American Geriatrics Society·Babar A KhanMalaz A Boustani
Nov 7, 2019·Cancer Medicine·Yoshinobu MatsudaUNKNOWN Phase-R Delirium Study Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.